Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tenofovir Exalidex. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 15/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 14/20 | 0.98 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tenofovir Exalidex SCHEMBL8268123 | 1.00 | CYP3A4 (0.98) | CYP3A4CYP2D6FGFR1 | |
| SCHEMBL23014999 | 0.99 | CYP3A4 (0.97) | CYP3A4CYP2D6 | |
| SCHEMBL24722045 | 0.99 | CYP3A4 (0.97) | CYP3A4CYP2D6 | |
| SCHEMBL23015000 | 0.99 | CYP3A4 (0.97) | CYP3A4CYP2D6 | |
| Ammonia Solution, Strong SCHEMBL23014957 | 0.98 | CYP3A4 (0.98) | CYP3A4CYP2D6 | |
| Ammonia Solution, Strong SCHEMBL29828174 | 0.98 | CYP3A4 (0.98) | CYP3A4CYP2D6 | |
| Ammonia Solution, Strong SCHEMBL23014956 | 0.98 | CYP3A4 (0.98) | CYP3A4CYP2D6 | |
| SCHEMBL16062939 | 0.96 | CYP3A4 (0.92) | CYP3A4CYP2D6 | |
| SCHEMBL16020665 | 0.96 | CYP3A4 (0.92) | CYP3A4CYP2D6 | |
| SCHEMBL24722139 | 0.96 | CYP3A4 (0.92) | CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 880 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4444311-B1 | GINSENOSIDES FOR TREATMENT OF CHRONIC HEPATITIS B VIRUS INFECTIONS | MENDEL UNIV IN BRNO (CZ) | 2026-05-06 | — | — | EP | claimed |
| US-12611453-B2 | Method of inducing an HIV-1-specific immune response using a chimpanzee adenovirus vector encoding an hivacat t-cell immunogen and TLR7 agonist | GILEAD SCIENCES, INC. (US) | 2026-04-28 | — | — | US | claimed |
| US-20260102422-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-04-16 | — | — | US | claimed |
| US-20260092059-A1 | Broad Spectrum Antiviral Compositions and Methods | EVRYS BIO, LLC (US) | 2026-04-02 | — | — | US | claimed |
| EP-4667471-A2 | BROAD SPECTRUM ANTIVIRAL COMPOSITIONS AND METHODS | Evrys Bio, LLC (US) | 2025-12-24 | — | — | EP | claimed |
| US-12459935-B2 | Broad spectrum antiviral compositions and methods | EVRYS BIO, LLC (US) | 2025-11-04 | — | — | US | claimed |
| US-20250325482-A1 | Tenofovir Spray Drying Sachet Enema Powder Formulation for HIV Prevention | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2025-10-23 | — | — | US | claimed |
| US-20250320497-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION AND HBV-ASSOCIATED DISEASES | VIR BIOTECHNOLOGY INC (US) | 2025-10-16 | — | — | US | claimed |
| US-20250302951-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS D VIRUS (HDV) INFECTION AND ASSOCIATED DISEASES | Vir Biotechnology, Inc. | 2025-10-02 | — | — | US | claimed |
| WO-2025151774-A1 | TREATING INFLAMMATORY RESPONSES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2025-07-17 | — | — | WO | claimed |
| EP-4017499-A1 | NUCLEOSIDE PRODRUGS AND USES RELATED THERETO | Emory University (US) | 2022-06-29 | — | — | EP | claimed |
| CN-114555608-A | Oxamide substituted tricyclic inhibitors of hepatitis b virus | 分子遗传国家研究所(INGM) | 2022-05-27 | — | — | CN | claimed |
| EP-3985010-A1 | SPIROCYCLIC INHIBITORS OF HEPATITIS B VIRUS | Promidis S.r.l. (IT) | 2022-04-20 | — | — | EP | claimed |
| US-20220110943-A1 | TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2022-04-14 | — | — | US | claimed |
| EP-3972640-A1 | COMBINATION OF A TLR7 MODULATING COMPOUND AND AN HIV VACCINE | GILEAD SCIENCES, INC. (US) | 2022-03-30 | — | — | EP | claimed |
| EP-3972979-A1 | OXALAMIDO-SUBSTITUTED TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS | Antios Therapeutics, Inc. (US) | 2022-03-30 | — | — | EP | claimed |
| EP-3969588-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION | VIR Biotechnology, Inc. (US) | 2022-03-23 | — | — | EP | claimed |
| US-20220062293-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2022-03-03 | — | — | US | claimed |
| WO-2022047279-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION WITH TOLL-LIKE-RECEPTOR AGONISTS | Accencio LLC (US) | 2022-03-03 | — | — | WO | claimed |
| US-20220056110-A1 | COMBINATION HBV THERAPY | HUMABS BIOMED SA (CH) | 2022-02-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102422-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | SARS1, ITK, SLC43A1 | CYP3A4 1770/4885CYP2D6 1619/4885FGFR1 2452/4885 |
| US-20260092059-A1 | Broad Spectrum Antiviral Compositions and Methods | IRF3, ZC3HAV1, ZC3HAV1L | CYP3A4 1156/4885CYP2D6 611/4885FGFR1 1429/4885 |
| US-12459935-B2 | Broad spectrum antiviral compositions and methods | IRF3, MAVS, ZC3HAV1 | CYP3A4 1569/4885CYP2D6 3292/4885FGFR1 1177/4885 |
| US-20220110943-A1 | TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS | HAVCR2, NR1H4, HCCS | CYP3A4 264/4885CYP2D6 1167/4885FGFR1 4062/4885 |
| US-12611453-B2 | Method of inducing an HIV-1-specific immune response using a chimpanzee adenovirus vector encoding an hivacat t-cell immunogen and TLR7 agonist | IRF3, STING1, MAVS | CYP3A4 3581/4885CYP2D6 3315/4885FGFR1 4419/4885 |
| US-20250302951-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS D VIRUS (HDV) INFECTION AND ASSOCIATED DISEASES | DNTT, HAVCR2, POLRMT | CYP3A4 4467/4885CYP2D6 4014/4885FGFR1 4459/4885 |
| US-20220056110-A1 | COMBINATION HBV THERAPY | HAVCR2, HLA-B, HDGF | CYP3A4 3704/4885CYP2D6 3721/4885FGFR1 4402/4885 |
| US-20220062293-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | TLR7, TLR3, TLR6 | CYP3A4 2399/4885CYP2D6 2698/4885FGFR1 2720/4885 |
| US-20250320497-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION AND HBV-ASSOCIATED DISEASES | IFNAR1, IFNG, HAVCR2 | CYP3A4 4333/4885CYP2D6 4334/4885FGFR1 4184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.